---
title: "Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293470541.md"
description: "Lakewood-Amedex Biotherapeutics released data on July 22, 2026, regarding its Phase 2-ready candidate Nu-3 for infected diabetic foot ulcers. The new resistance data indicates no induced resistance in serial-passage studies, supporting the drug's membrane-disruption mechanism and its potential in antimicrobial-resistance-focused development."
datetime: "2026-07-22T12:04:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293470541.md)
  - [en](https://longbridge.com/en/news/293470541.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293470541.md)
generator: "portal-rs"
---

# Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance data

-   Lakewood-Amedex published a July 22, 2026 release highlighting new resistance data for Nu-3, its Phase 2-ready infected diabetic foot ulcer candidate. \* Nu-3 showed no induced resistance in a serial-passage study, supporting its membrane-disruption mechanism and positioning in antimicrobial-resistance-focused development. \* Release: here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY09340) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [LABT.US](https://longbridge.com/en/quote/LABT.US.md)

## Related News & Research

- [Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company](https://longbridge.com/en/news/296957982.md)
- [Lakewood-Amedex Biotherapeutics announces annual shareholder meeting](https://longbridge.com/en/news/295452742.md)
- [FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial | FBLG Stock News](https://longbridge.com/en/news/297189991.md)
- [Artisan Partners cuts Sodexo stake to 9.99% of capital](https://longbridge.com/en/news/297199254.md)
- [FibroBiologics ships third CYWC628 batch to Australia for Phase 1/2 diabetic foot ulcer trial](https://longbridge.com/en/news/297186294.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**